N/A
N=279
Facilitating Assessment of At-Risk Sailors Using Technology
Psychological Distress
Bottom Line
View on ClinicalTrials.gov: NCT04159480 ↗Enrolled (actual)
279
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Percentage of Cogito Participants Reported Being Satisfied — 52 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Experimental - Cogito Companion (Device); Active Control (Behavioral)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Eastern Colorado Health Care System
- Primary completion
- Mar 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Cogito Participants Reported Being Satisfied |
52 | — |
Summary
Randomized clinical trial with individuals being allocated to experimental (Cogito Companion) or Active Control arms. Those in the latter will receive information regarding widely available mobile self-help apps via a custom mobile app built in MyCAP. This same platform will be used to collect data regarding symptoms. Randomization will be stratified by gender, force (Surface, Aviation), and smartphone model (Android, I-Phone), as Cogito algorithms differ based on smartphone platforms. Participants will be willing Naval personnel being redeployed to CONUS. Data is also being collected (feasibility/acceptability) to inform future implementation..
Eligibility Criteria
Inclusion Criteria.
- Member of the Navel Surface or Aviation Forces;
- Age: 18-55 years at the time of enrollment;
- Ability to provide verbal and electronic informed consents;
- Ownership of smartphone;
- Willingness to use smartphone and personal data plan to participate.
Exclusion Criteria.
- Having redeployed (returning to the Continental United States) more than twelve months (approximately) prior to consent.
- Having an iPhone (until later in 2019 when the Cogito Corporation plans to release the iOS version of the Cogito Companion app).
Data sourced from ClinicalTrials.gov (NCT04159480). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.